指南与共识MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

原发或继发性骨髓纤维化拟行异基因造血细胞移植患者的脾肿大:EBMT慢性恶性肿瘤工作组的立场声明

Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT.
指南 / 共识 · Lancet Haematol · 2022-12-06

该立场声明由EBMT慢性恶性肿瘤工作组组织血液科、移植科、消化科、外科、放疗科和放射科专家共同制定,针对拟行异基因造血细胞移植的骨髓纤维化患者脾肿大的评估与移植前处理提出共识。声明强调所有患者移植前须评估脾脏大小,脾肿大≥5 cm(尤其超过左肋缘下15 cm)或伴脾肿大相关症状者可考虑移植前治疗以缩小脾脏,脾进行性增大者应评估二线选择,脾静脉血栓并非移植绝对禁忌但需多学科管理,COVID-19防控应遵循免疫抑制患者标准建议。

要点

  • 所有拟行异基因造血细胞移植的骨髓纤维化患者移植前必须评估脾脏大小。
  • 脾肿大≥5 cm(尤其超过左肋缘下15 cm)或伴脾肿大相关症状者可考虑移植前治疗以缩小脾脏。
  • 脾静脉血栓并非移植绝对禁忌,但需多学科协作管理。

核心结论

  • 该立场声明针对拟行异基因造血细胞移植的骨髓纤维化患者脾肿大的评估与移植前处理提出共享立场。

研究设计与样本

  • 该立场声明由EBMT慢性恶性肿瘤工作组组织国际多学科专家组制定,专家来自血液科、移植科、消化科、外科、放疗科和放射科。

主要发现

  • 与脾脏未显著肿大的患者相比,脾脏明显增大可能与移植后植入延迟和植入失败风险更高、非复发死亡率增加及总生存更差相关。
  • 目前尚无标准化指南协助移植医生决定异基因造血细胞移植前脾肿大的最佳管理。

关键数值与推荐

  • 所有骨髓纤维化患者在异基因造血细胞移植前必须评估脾脏大小。
  • 骨髓纤维化患者脾肿大≥5 cm,尤其超过左肋缘下15 cm,或伴有脾肿大相关症状者,可从移植前以缩小脾脏为目标的治疗中获益。
  • 无应答或应答丢失、脾脏增大的患者应根据可及性、患者体能和中心经验评估二线选择。
  • 脾静脉血栓不是异基因造血细胞移植的绝对禁忌证,但需要多学科方法。
  • COVID-19的预防和治疗应遵循针对免疫抑制患者的标准建议。

临床怎么用

  • 拟行异基因造血细胞移植的骨髓纤维化患者移植前必须评估脾脏大小。
  • 脾肿大≥5 cm(尤其超过左肋缘下15 cm)或伴脾肿大相关症状者可考虑移植前治疗以缩小脾脏。
  • 无应答或应答丢失且脾脏增大者应评估二线选择。
  • 脾静脉血栓患者需多学科协作评估移植。
  • 免疫抑制患者的COVID-19预防和治疗应遵循标准建议。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Splenomegaly is a hallmark of myelofibrosis, a debilitating haematological malignancy for which the only curative option is allogeneic haematopoietic cell transplantation (HCT). Considerable splenic enlargement might be associated with a higher risk of delayed engraftment and graft failure, increased non-relapse mortality, and worse overall survival after HCT as compared with patients without significantly enlarged splenomegaly. Currently, there are no standardised guidelines to assist transplantation physicians in deciding optimal management of splenomegaly before HCT. Therefore, the aim of this Position Paper is to offer a shared position statement on this issue. An international group of haematologists, transplantation physicians, gastroenterologists, surgeons, radiotherapists, and radiologists with experience in the treatment of myelofibrosis contributed to this Position Paper. The key issues addressed by this group included the assessment, prevalence, and clinical significance of splenomegaly, and the need for a therapeutic intervention before HCT for the control of splenomegaly. Specific scenarios, including splanchnic vein thrombosis and COVID-19, are also discussed. All patients with myelofibrosis must have their spleen size assessed before allogeneic HCT. Myelofibrosis patients with splenomegaly measuring 5 cm and larger, particularly when exceeding 15 cm below the left costal margin, or with splenomegaly-related symptoms, could benefit from treatment with the aim of reducing the spleen size before HCT. In the absence of, or loss of, response, patients with increasing spleen size should be evaluated for second-line options, depending on availability, patient fitness, and centre experience. Splanchnic vein thrombosis is not an absolute contraindication for HCT, but a multidisciplinary approach is warranted. Finally, prevention and treatment of COVID-19 should adhere to standard recommendations for immunocompromised patients.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Polverelli N, Hernández-Boluda JC, Czerw T, et al. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2022. PMID: 36493799. doi:10.1016/S2352-3026(22)00330-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。